Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100399 | 0.78 | SIGMAR1 (0.46) | EPHX2EPHX1ALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL10144656 | 0.77 | EPHX1 (0.47) | EPHX2EPHX1ALDH1A1KDM4EKMT2A | |
| Iodide SCHEMBL27688322 | 0.77 | SIGMAR1 (0.45) | EPHX2EPHX1ALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL10383489 | 0.76 | ALDH1A1 (0.50) | EPHX2EPHX1ALDH1A1KDM4EKMT2A | |
| SCHEMBL4103966 | 0.76 | SIGMAR1 (0.43) | EPHX2EPHX1ALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL2740861 | 0.73 | EPHX1 (0.55) | EPHX2EPHX1ALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL14868300 | 0.73 | SIGMAR1 (0.42) | EPHX2EPHX1ALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL26044029 | 0.72 | — | — | |
| SCHEMBL14868296 | 0.71 | SIGMAR1 (0.39) | EPHX2EPHX1ALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL3915783 | 0.71 | EPHX1 (0.50) | EPHX2EPHX1ALDH1A1KDM4ESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170209394-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209394-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GCG | EPHX2 1909/4885EPHX1 2126/4885ALDH1A1 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.